William E Russell, Brian N Bundy, Mark S Anderson, Laura A Cooney, Stephen E Gitelman, Robin S Goland, Peter A Gottlieb, Carla J Greenbaum, Michael J Haller, Jeffrey P Krischer, Ingrid M Libman, Peter S Linsley, S Alice Long, Sandra M Lord, Daniel J Moore, Wayne V Moore, Antoinette M Moran, Andrew B Muir, Philip Raskin, Jay S Skyler, John M Wentworth, Diane K Wherrett, Darrell M Wilson, Anette-Gabriele Ziegler, Kevan C Herold
OBJECTIVE: Previous studies showed that inhibiting lymphocyte costimulation reduces declining β-cell function in individuals newly diagnosed with type 1 diabetes. We tested whether abatacept would delay or prevent progression of type 1 diabetes from normal glucose tolerance (NGT) to abnormal glucose tolerance (AGT) or to diabetes and the effects of treatment on immune and metabolic responses. RESEARCH DESIGN AND METHODS: We conducted a phase 2, randomized, placebo-controlled, double-masked trial of abatacept in antibody-positive participants with NGT who received monthly abatacept/placebo infusions for 12 months...
March 15, 2023: Diabetes Care